These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 17563075)

  • 21. Myelodysplastic features developing in Philadephia-negative cells during imatinib mesylate therapy for CML: report of a new case.
    Mozziconacci MJ; Caillères S; Maurice C; Vey N; Sainty D; Blaise D; Lafage-Pochitaloff M
    Leukemia; 2003 Sep; 17(9):1901-2. PubMed ID: 12970792
    [No Abstract]   [Full Text] [Related]  

  • 22. A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript.
    Li X; Yang J; Chen X; Liu J; Li H; Zheng J; He Y; Chen Z; Huang S
    Cancer Genet Cytogenet; 2007 Jul; 176(2):166-8. PubMed ID: 17656262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Emergence and decrement of Ph-negative clone with trisomy 8 in CML during imatinib therapy].
    Kimura F; Kobayashi S; Ogura K; Kobayashi A; Torikai H; Ikeda T; Sato K; Motoyoshi K
    Rinsho Ketsueki; 2004 Sep; 45(9):1058-60. PubMed ID: 15510836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trisomy 8 in Philadelphia-negative cells during imatinib therapy.
    Bernardeschi P; Fiorentini G; Rossi S; Dentico P; Simi P; Guidi S
    Am J Hematol; 2004 Sep; 77(1):88-9. PubMed ID: 15307114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of Ph-negative abnormal clones emerging during imatinib therapy.
    Abruzzese E; Gozzetti A; Galimberti S; Trawinska MM; Caravita T; Siniscalchi A; Cervetti G; Mauriello A; Coletta AM; De Fabritiis P
    Cancer; 2007 Jun; 109(12):2466-72. PubMed ID: 17503437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
    Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
    Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clonal karyotypic abnormalities in Philadelphia negative cells of CML patients treated with imatinib: is it under-reported and does it have any clinical significance?
    O'Shea D; Crotty G; Carroll P; Conneally E; McCann S; Neat MJ
    Br J Haematol; 2004 Nov; 127(3):367-9. PubMed ID: 15491304
    [No Abstract]   [Full Text] [Related]  

  • 28. Development of acute myeloid leukemia associated with Ph-negative clone with inv(3)(q21q26) during imatinib therapy for chronic myeloid leukemia.
    Dvorak P; Hruba M; Subrt I
    Leuk Res; 2009 Jun; 33(6):860-1. PubMed ID: 18977531
    [No Abstract]   [Full Text] [Related]  

  • 29. Random aneuploidy in CML patients at diagnosis and under imatinib treatment.
    Amiel A; Yukla M; Gaber E; Leopold L; Josef G; Fejgin M; Lishner M
    Cancer Genet Cytogenet; 2006 Jul; 168(2):120-3. PubMed ID: 16843101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.
    Kovitz C; Kantarjian H; Garcia-Manero G; Abruzzo LV; Cortes J
    Blood; 2006 Oct; 108(8):2811-3. PubMed ID: 16809614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An inv(16) in Ph-negative cells of a chronic myelogenous leukemia patient after imatinib treatment.
    Rowe LR; Brothman AR; Nibley WE; Gaffney MR; Chen Z
    Cancer Genet Cytogenet; 2007 Apr; 174(1):54-6. PubMed ID: 17350467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clonal chromosomal abnormalities in the Philadelphia chromosome negative cells of chronic myeloid leukemia patients treated with imatinib.
    Guilbert-Douet N; Morel F; Le Bris MJ; Berthou C; Morice P; Bourquard P; Braekeleer MD
    Leukemia; 2004 Jun; 18(6):1140-2. PubMed ID: 15085159
    [No Abstract]   [Full Text] [Related]  

  • 33. [Disappearance of a Philadelphia chromosome-positive clone and appearance of a -negative clone following treatment with imatinib mesylate in acute myelomonocytic leukemia].
    Takahashi W; Arai Y; Tadokoro J; Takeuchi K; Yamagata T; Mitani K
    Rinsho Ketsueki; 2006 Feb; 47(2):111-4. PubMed ID: 16529013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trisomy 8 finding treatment of imatinib mesylate in chronic myeloid leukemia cases.
    Tunca Y; Güran S
    Exp Hematol; 2005 Feb; 33(2):151. PubMed ID: 15676207
    [No Abstract]   [Full Text] [Related]  

  • 35. Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up.
    Moser AM; Manor E; Narkis G; Kapelushnik J
    Cancer Genet Cytogenet; 2006 Oct; 170(1):54-7. PubMed ID: 16965955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic myeloid leukemia with a novel four-way t(6;13;9;22)(p21;q32;q34;q11.2) successfully treated with imatinib mesylate.
    Kubota Y; Waki M
    Cancer Genet Cytogenet; 2010 Sep; 201(2):135-6. PubMed ID: 20682400
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of chronic myeloid leukemia in the imatinib era: perspective from a developing country.
    Aziz Z; Iqbal J; Akram M; Saeed S
    Cancer; 2007 Mar; 109(6):1138-45. PubMed ID: 17315159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clonal Ph-negative hematopoiesis with trisomy 8 in chronic myeloid leukemia during imatinib therapy].
    Yamamoto Y; Ishii K; Nomura S; Fukuhara S
    Rinsho Ketsueki; 2004 Feb; 45(2):164-6. PubMed ID: 15045827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
    Kantarjian H; O'Brien S; Shan J; Huang X; Garcia-Manero G; Faderl S; Ravandi-Kashani F; Verstovsek S; Beth Rios M; Cortes J
    Cancer; 2008 Feb; 112(4):837-45. PubMed ID: 18085610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) treated with imatinib mesylate (IM): a report with IM plasma concentration and bcr-abl transcripts.
    Kondo T; Tasaka T; Sano F; Matsuda K; Kubo Y; Matsuhashi Y; Nakanishi H; Sadahira Y; Wada H; Sugihara T; Tohyama K
    Leuk Res; 2009 Sep; 33(9):e137-8. PubMed ID: 19371951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.